Advertisement Mylan receives final FDA approval for Tranexamic Acid Injection - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Mylan receives final FDA approval for Tranexamic Acid Injection

Mylan Institutional has received final US Food and Drug Administration (FDA) approval for its abbreviated new drug application for Tranexamic Acid Injection, 100 mg/mL.

Tranexamic Acid Injection, 100 mg/mL are packaged in 1,000 mg/10 mL Single-dose Vials.

This product is the generic version of Pharmacia & Upjohn’s Cyklokapron Injection.

Tranexamic Acid Injection is indicated for short-term use in patients with hemophilia to reduce or prevent hemorrhage during and following oral surgery.